131 related articles for article (PubMed ID: 8383740)
1. Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate.
O'Donnell JM
J Pharmacol Exp Ther; 1993 Mar; 264(3):1168-78. PubMed ID: 8383740
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies.
Kumari M; Cover PO; Poyser RH; Buckingham JC
Br J Pharmacol; 1997 Jun; 121(3):459-68. PubMed ID: 9179387
[TBL] [Abstract][Full Text] [Related]
3. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases.
O'Donnell JM; Frith S
Pharmacol Biochem Behav; 1999 May; 63(1):185-92. PubMed ID: 10340540
[TBL] [Abstract][Full Text] [Related]
4. Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.
Zhang HT; Huang Y; Mishler K; Roerig SC; O'Donnell JM
Psychopharmacology (Berl); 2005 Oct; 182(1):104-15. PubMed ID: 16010541
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule.
O'Donnell JM; Marek GJ; Seiden LS
Neurosci Biobehav Rev; 2005; 29(4-5):785-98. PubMed ID: 15893376
[TBL] [Abstract][Full Text] [Related]
6. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
Rose RJ; Liu H; Palmer D; Maurice DH
Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
[TBL] [Abstract][Full Text] [Related]
7. Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase in rat cerebral cortex.
Ye Y; O'Donnell JM
J Neurochem; 1996 May; 66(5):1894-902. PubMed ID: 8780016
[TBL] [Abstract][Full Text] [Related]
8. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
Makhay MM; Houslay MD; O'Donnell JM
Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
[TBL] [Abstract][Full Text] [Related]
9. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
[TBL] [Abstract][Full Text] [Related]
10. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
11. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats.
Itoh T; Tokumura M; Abe K
Eur J Pharmacol; 2004 Sep; 498(1-3):135-42. PubMed ID: 15363987
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
13. Differential-reinforcement-of-low-rate 72-second schedule: selective effects of antidepressant drugs.
O'Donnell JM; Seiden LS
J Pharmacol Exp Ther; 1983 Jan; 224(1):80-8. PubMed ID: 6848751
[TBL] [Abstract][Full Text] [Related]
14. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
15. The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
Gordeladze JO
Biosci Rep; 1990 Aug; 10(4):375-88. PubMed ID: 2174276
[TBL] [Abstract][Full Text] [Related]
16. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.
Wachtel H
Neuropharmacology; 1983 Mar; 22(3):267-72. PubMed ID: 6302550
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
J Pharmacol Exp Ther; 1997 Jul; 282(1):505-12. PubMed ID: 9223593
[TBL] [Abstract][Full Text] [Related]
18. Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor.
Wright KF; Turner CR; Jayasinghe-Beck R; Cohen VL; Cheng JB; Watson JW
Can J Physiol Pharmacol; 1997 Aug; 75(8):1001-8. PubMed ID: 9360015
[TBL] [Abstract][Full Text] [Related]
19. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors.
Wachtel H
Psychopharmacology (Berl); 1982; 77(4):309-16. PubMed ID: 6182575
[TBL] [Abstract][Full Text] [Related]
20. CDP840: a novel inhibitor of PDE-4.
Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
